Tenofovir pharmacokinetics in HIV-infected Thai adults with moderate renal function impairment receiving either a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-based or Lopinavir/Ritonavir-based antiretroviral therapy

Project no.: HIV-NAT 172/ALTER Study

The study is a phase I, non-randomized, open-label, pharmacokinetic study to evaluate the pharmacokinetics of tenofovir (TDF) in HIV-infected Thai adults with a creatinine clearance between 30 to < 50mL/min when administered at the recommended dose of 300 mg every 48 hours, and at an alternative dose of 150 mg every 24 hours, as part of a NNRTI-based HAART regimen or a lopinavir/ritonavir-based HAART regimen.

Presentation: submitted to CROI 2015